ESR1 and breast carcinoma: Both western blot and immunofluorescence assay results revealed that E-cadherin was upregulated in a dose-dependent manner (Figures 3A,B), which is in consistent with results in the human ERα-negative breast cancer MDA-MB-231 and MDA-MB-468 cells.